One big problem is the US subsidizes the cost of development while much of the rest of the world free rides off of that development. I work in pharma. If a drug won't be reimbursed in the US at ridiculous US prices, the company simply won't develop it, and it will never come to market, so there will be no problem with a new and expensive drug.
Xarelto is a good example. There is a perfectly good alternative: coumadin. It's basically free. But you have to monitor blood levels (not really levels, INR) and have to be careful about not varying vitamin K content in diet. But US payers were willing to pay for a safer, more convenient drug, so Xarelto was developed. In the future, it will be generic and cost $4/month at Walgreens, and we will be angry at an even better new drug that costs a lot.
All that being said, I understand your frustration and don't mean to minimize it. It's not right that you have to bear an undue share of the cost, just because of the way the system is set up. Fortunately, there are a lot of patient assistance programs, and I hope you find one that can make the drug more acceptable. I also agree that the companies often game the system by developing monopolies on generics (like colchicine), and I find that practice repulsive.
Xarelto is a good example. There is a perfectly good alternative: coumadin. It's basically free. But you have to monitor blood levels (not really levels, INR) and have to be careful about not varying vitamin K content in diet. But US payers were willing to pay for a safer, more convenient drug, so Xarelto was developed. In the future, it will be generic and cost $4/month at Walgreens, and we will be angry at an even better new drug that costs a lot.
All that being said, I understand your frustration and don't mean to minimize it. It's not right that you have to bear an undue share of the cost, just because of the way the system is set up. Fortunately, there are a lot of patient assistance programs, and I hope you find one that can make the drug more acceptable. I also agree that the companies often game the system by developing monopolies on generics (like colchicine), and I find that practice repulsive.